Hostname: page-component-5b777bbd6c-sbgtn Total loading time: 0 Render date: 2025-06-18T06:32:49.299Z Has data issue: false hasContentIssue false
  • English
  • Français

Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression

Published online by Cambridge University Press:  16 April 2020

M. Kluge ,
P. Schuessler  and
A. Steiger
M. Kluge
Affiliation:
Max Planck Institute of Psychiatry, Munich, Germany
P. Schuessler
Affiliation:
Max Planck Institute of Psychiatry, Munich, Germany
A. Steiger
Affiliation:
Max Planck Institute of Psychiatry, Munich, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background and aims:

Sleep studies in patients with major depression receiving the new selective norepinephrine and serotonin reuptake inhibitor (SNRI) duloxetine are lacking.

Methods:

Polysomnography in 10 patients with major depression (7 males, 39.9 ± 7.6 years, HAMD-21 score: 23.6 ± 5.6) was recorded twice, before and after 7-14 days of treatment with duloxetine.

Results:

A significant (p < 0.01) increase from baseline to endpoint was found for amount of stage 3 sleep (21.0 ± 10.7 to 37.4 ± 20.1 minutes) and REM latency (58.5 ± 31.1 to 193.6 ± 72.6 minutes). Amount of REM sleep significantly (p < 0.01) decreased from 94.8 ± 34.5 to 51.5 ± 42.5 minutes.

Conclusions:

These results partly differ from those in healthy subjects receiving duloxetine.

Type
Poster Session 2: Depressive Disorders
Information
European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S234
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.